Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
37 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Xencor, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Xencor, Inc. - Product Pipeline Review - 2014', provides an overview of the Xencor, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Xencor, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Xencor, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Xencor, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Xencor, Inc.'s pipeline products Reasons to buy - Evaluate Xencor, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Xencor, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Xencor, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Xencor, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Xencor, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Xencor, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Xencor, Inc. Snapshot 5 Xencor, Inc. Overview 5 Key Information 5 Key Facts 5 Xencor, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Xencor, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Xencor, Inc. - Pipeline Products Glance 15 Xencor, Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Xencor, Inc. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Discovery Products/Combination Treatment Modalities 18 Xencor, Inc. - Drug Profiles 19 XmAb-5871 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Monoclonal Antibody 2 for Oncology 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Monoclonal Antibody for Oncology 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 XmAb-7195 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Monoclonal Antibody Targeting CD3 and CD123 Acute Myeloid Leukemia 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Monoclonal Antibody Targeting CD3 and CD38 for Multiple Myeloma 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 XENP-1138 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Xtend-TNF 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Anti-X/CD32b Monoclonal Antibody 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Xencor, Inc. - Pipeline Analysis 28 Xencor, Inc. - Pipeline Products by Target 28 Xencor, Inc. - Pipeline Products by Route of Administration 29 Xencor, Inc. - Pipeline Products by Molecule Type 30 Xencor, Inc. - Pipeline Products by Mechanism of Action 31 Xencor, Inc. - Recent Pipeline Updates 32 Xencor, Inc. - Dormant Projects 34 Xencor, Inc. - Locations And Subsidiaries 35 Head Office 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 37 Disclaimer 37
List of Tables Xencor, Inc., Key Information 5 Xencor, Inc., Key Facts 5 Xencor, Inc. - Pipeline by Indication, 2014 8 Xencor, Inc. - Pipeline by Stage of Development, 2014 9 Xencor, Inc. - Monotherapy Products in Pipeline, 2014 10 Xencor, Inc. - Partnered Products in Pipeline, 2014 11 Xencor, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12 Xencor, Inc. - Out-Licensed Products in Pipeline, 2014 13 Xencor, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 Xencor, Inc. - Phase II, 2014 15 Xencor, Inc. - Phase I, 2014 16 Xencor, Inc. - Preclinical, 2014 17 Xencor, Inc. - Discovery, 2014 18 Xencor, Inc. - Pipeline by Target, 2014 28 Xencor, Inc. - Pipeline by Route of Administration, 2014 29 Xencor, Inc. - Pipeline by Molecule Type, 2014 30 Xencor, Inc. - Pipeline Products by Mechanism of Action, 2014 31 Xencor, Inc. - Recent Pipeline Updates, 2014 32 Xencor, Inc. - Dormant Developmental Projects,2014 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.